A new study led by researchers at the Icahn School of Medicine at Mount Sinai has found that adding the targeted therapy ...

Cancer’s future may lie in combination therapy—pairing treatments to outsmart tumors, boost survival, and bring new hope ...

Pfizer said on Tuesday its cancer drug Padcev, in combination with Merck's Keytruda, significantly improved survival rates in ...

The efficacy and safety of rivaroxaban monotherapy are consistent across all age groups of patients with atrial fibrillation and stable coronary artery disease, a study confirms.

Q2 2025 Management View Shantanu K. Gaur, CEO, stated that "our new strategy doubles down on metabolically healthy weight loss, losing weight, keeping it off and maintaining muscle mass, with a ...

Treating psoriatic arthritis (PsA) patients with more than one targeted therapy appears to be just fine, with no increased ...

They urge people to be wary of misinformation, like false claims on social media posts that hormones will prevent dementia ...

Researchers found that adding a third immune-targeting drug to existing therapies helped shrink tumors in lab models of ...

Immune checkpoint blockade medications have revolutionized cancer treatment, giving patients and providers new hope to control and sometimes cure metastatic cancer. However, predicting which patients ...

Early results from the TUSCANY trial highlight promising remission rates and safety for a new triplet therapy in treating ...

Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing ...

Treatment for advanced bladder cancer had not significantly changed for 40 years. Now thousands are set to benefit ...